Royalty Pharma plc (RPRX)

Market Cap	11.70B
Revenue (ttm)	2.24B
Net Income (ttm)	798.86M
Shares Out	452.11M
EPS (ttm)	1.77
PE Ratio	14.62
Forward PE	6.29
Dividend	$0.84 (3.25%)
Ex-Dividend Date	May 16, 2024

Volume	1,982,304
Open	26.11
Previous Close	26.19
Day's Range	25.83 - 26.24
52-Week Range	25.83 - 31.66
Beta	0.47
Analysts	Strong Buy
Price Target	43.00 (+66.15%)
Earnings Date	Aug 6, 2024

About RPRX

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 2020
• Employees: 89
• Stock Exchange: NASDAQ
• Ticker Symbol: RPRX

Financial Performance

In 2023, Royalty Pharma's revenue was $2.35 billion, an increase of 5.24% compared to the previous year's $2.24 billion. Earnings were $1.13 billion, an increase of 2549.50%.

Analyst Forecast

According to 5 analysts, the average rating for RPRX stock is "Strong Buy." The 12-month stock price forecast is $43.0, which is an increase of 66.15% from the latest price.

Price Target

$43.0

(66.15% upside)

Analyst Consensus: Strong Buy